Corbus CRB-601-01 (Solid Tumors)

Purpose of this Study

We are doing this study to find out if an experimental drug called CRB-601 (the study drug) is a safe and effective option for people who have cancers with advanced solid tumors that did not improve with standard treatment.

Who Can Participate?

Eligibility

Adults ages 18-64 who:
  • Are diagnosed with an advanced or metastatic solid tumor
  • Had their disease progress after at least 1 line of previous treatment
For more information about who can join this study, please contact the Center for Cancer Immunotherapy at CCI-TrialReferrals@duke.edu.

Age Range

18-64

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will get an assignment to 1 of 3 different dose levels of the study drug. These dose levels might be:
  • 3 milligrams for each kilogram of body weight (3 mg/kg); OR
  • 10 mg/kg; OR
  • 30 mg/kg
The dose level you receive will depend on when you join the study. The study team can let you know what dose level is open when you make your decision. The study drug is given as an intravenous (IV) infusion every 2 weeks.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of CRB-601, a Monoclonal Antibody against Integrin avß8, in Patients with Advanced Solid Tumors

Principal Investigator

Jeffrey
Clarke

Protocol Number

PRO00116951

NCT ID

NCT06603844

Phase

I/II

Enrollment Status

Pending Open to Enrollment
ClinicalTrials.gov